Who
Robert Barrow
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Definium Therapeutics.
In numbers
- Trades disclosed
- 57
- Buys
- 2
- Sells
- 29
- Bought
- $6,215
- Sold
- $9.1M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 15 Jan 2022
- Last trade
- 25 Sep 2026
- Last filed
- 29 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Sep 2026filed 29 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.2M31,550 at $36.57 | filing |
| 25 Sep 2026filed 29 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.2M31,550 at $36.57 | filing |
| 14 Sep 2026filed 14 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 14 Sep 2026filed 14 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 3 Sep 2026filed 4 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $722K19,023 at $37.94 | filing |
| 3 Sep 2026filed 4 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $722K19,023 at $37.94 | filing |
| 2 Sep 2026filed 4 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 12 Aug 2026filed 12 Aug 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —375,000 at $0.00 | filing |
| 12 Aug 2026filed 12 Aug 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —375,000 at $0.00 | filing |
| 25 Jun 2026filed 26 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.3M29,208 at $45.03 | filing |
| 25 Jun 2026filed 26 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.3M29,208 at $45.03 | filing |
| 22 Jun 2026filed 22 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —375,000 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —375,000 at $0.00 | filing |
| 25 Mar 2026filed 26 Mar 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $451K24,431 at $18.47 | filing |
| 25 Mar 2026filed 26 Mar 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $451K24,431 at $18.47 | filing |
| 3 Feb 2026filed 5 Feb 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —320,000 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —320,000 at $0.00 | filing |
| 26 Dec 2025filed 29 Dec 2025 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $339K25,791 at $13.15 | filing |
| 25 Sep 2025filed 26 Sep 2025 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $252K25,797 at $9.77 | filing |
News
No headline names them, or the companies they trade most, lately.